You are in the accessibility menu

Please use this identifier to cite or link to this item:
Risk of metabolic syndrome in postmenopausal breast cancer survivors
Universidade Estadual Paulista (UNESP)
  • 1072-3714
  • 1530-0374
The aim of this study was to assess the risk of metabolic syndrome (MetS) in postmenopausal breast cancer survivors as compared with postmenopausal women without breast cancer. METHODS: In this cross-sectional study, 104 postmenopausal breast cancer survivors were compared with 208 postmenopausal women (controls) attending a university hospital. Eligibility criteria included the following: amenorrhea longer than 12 months and aged 45 years or older, treated for breast cancer, and metastasis-free for at least 5 years. The control group consisted of women with amenorrhea longer than 12 months and aged 45 years or older and without breast cancer, matched by age and menopause status (in a proportion of 1:2 as sample calculation). Clinical and anthropometric data were collected. Biochemical parameters, including total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, glucose, and C-reactive protein, were measured. Women showing three or more diagnostic criteria were diagnosed as having MetS: waist circumference of 88 cm or larger, blood pressure of 130/85 mm Hg or higher, triglycerides level of 150 mg/dL or higher, high-density lipoprotein cholesterol level lower than 50 mg/dL, and glucose level of 100 mg/dL or higher. For statistical analysis, Student's t test, χ2 test, and logistic regression (odds ratio [OR]) were used. RESULTS: The mean (SD) age of breast cancer survivors was 60.6 (8.6) years, with a mean (SD) follow-up of 9.4 (4.4) years. A higher percentage of breast cancer survivors (46.2%) were obese as compared with controls (32.7%; P < 0.05), and a smaller percentage showed optimal values for low-density lipoprotein cholesterol, glucose, and C-reactive protein versus controls (P < 0.05). MetS was diagnosed in 50% of breast cancer survivors and in 37.5% of control group women (P < 0.05). Among the MetS diagnostic criteria, the most prevalent was abdominal obesity (waist circumference >88 cm), affecting 62.5% and 67.8% of the participants, respectively. In the control group, breast cancer survivors had a higher risk for MetS (OR, 1.66; 95% CI, 1.04-2.68), dysglycemia (OR, 1.05; 95% CI, 1.09-3.03), and hypertension (OR, 1.71; 95% CI, 1.02-2.89). CONCLUSIONS: Postmenopausal breast cancer survivors present a higher risk of developing MetS as compared with women without breast cancer. © 2012 by The North American Menopause Society.
Issue Date: 
Menopause, v. 20, n. 4, p. 448-454, 2013.
Time Duration: 
  • Breast cancer survivors
  • Menopause
  • Metabolic syndrome
  • Risk factors
  • C reactive protein
  • cholesterol
  • estrogen receptor
  • glucose
  • high density lipoprotein cholesterol
  • low density lipoprotein cholesterol
  • progesterone receptor
  • triacylglycerol
  • abdominal obesity
  • adult
  • amenorrhea
  • arterial pressure
  • axillary lymph node
  • blood pressure
  • body mass
  • breast cancer
  • cancer chemotherapy
  • cancer hormone therapy
  • cancer radiotherapy
  • cancer size
  • cancer survivor
  • cardiometabolic risk
  • cholesterol blood level
  • conservative treatment
  • controlled study
  • cross-sectional study
  • disease duration
  • disease severity
  • exercise
  • female
  • follow up
  • glucose blood level
  • hormone substitution
  • human
  • hypertension
  • major clinical study
  • mastectomy
  • metabolic syndrome X
  • parity
  • postmenopause
  • protein blood level
  • risk assessment
  • triacylglycerol blood level
  • waist circumference
Access Rights: 
Acesso restrito
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.